dMMR is associated in tumors with a high number of activated CD8+ cytotoxic t cells and upregulated immune checkpoints, providing a theoretical guide for PD-1 and PD-L1 blockade therapies in gastrointestinal tumors (Le et al., 2015). This evidence concerns the gene CD274 and digestive system neoplasm.